Registration Dossier

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Additional information

Bromepoxid (ZK 137314) did not show a mutagenic potential in a bacterial reverse mutation assay (Ames test in S. typhimurim strains TA 1535, TA 100, TA 1537, TA 1538 and TA98) when tested up to the cytotoxic and precipitating dose levels in the absense or presence of extrinsic metabolic activation (liver S9 mix from Aroclor 1254 -treated rats). Growth inhibition was seen at the highest dose tested (2.5 mg/plate) in the strains TA 1537, TA 1538 and TA 98. Precipitates in the agar could be observed starting at 0.5 mg/plate in all strains tested.

Short description of key information:
Gene mutation (bacterial reverse mutation assay / Ames test, GLP, OECD TG471): negative with and without metabolic activation
[Schering AG, Report No. X249 -draft-, 1997-10-01]

Endpoint Conclusion: No adverse effect observed (negative)

Justification for classification or non-classification

Based on the results there is no classification required according to Directive 67/548/EEC and Regulation (EC) 1272/2008 (CLP).